Other clinical trials on targeted IL-6 interventions for asthma are not currently well underway, and a phase 2a study evaluating the impact of Sirukumab in subjects with poorly controlled severe asthma was terminated in early may due to safety concerns (NCT02794519). The gene discussed is IL6; the disease is asthma.